<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135898</url>
  </required_header>
  <id_info>
    <org_study_id>SIBP-04-01</org_study_id>
    <nct_id>NCT04135898</nct_id>
  </id_info>
  <brief_title>A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Phase I Study Comparing the Pharmacokinetic and Safety of SIBP-04 and Bevacizumab in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute Of Biological Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute Of Biological Products</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, positive drug parallel controlled clinical trial in
      China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups
      in a ratio of 1:1 to receive the test drug and the positive control.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2019</start_date>
  <completion_date type="Anticipated">October 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Area under the concentration time curve of the analyte in serum over the time interval from 0 to the last measurable concentration at time &quot;t&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Maximum measured concentration of the analyte in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Area under the concentration time curve of the analyte in serum over the time interval from 0 to extrapolated to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Time from dosing to maximum measured concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Terminal half life of the analyte in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Total clearance of the analyte in serum following IV infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Volume of distribution during the terminal phase λz following an intravascular dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From 0 to day 71</time_frame>
    <description>Incidence of anti drug antibodies (ADAs) and neutralizing anti drug antibodies（NAb）</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Male</condition>
  <arm_group>
    <arm_group_label>SIBP-04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIBP-04</intervention_name>
    <description>3mg/kg, infusion in 90 minutes</description>
    <arm_group_label>SIBP-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>3mg/kg, infusion in 90 minutes</description>
    <arm_group_label>Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are able and willing to give written informed consent.

          2. 18-45 years old, male.

          3. Body mass index (BMI): 18-26 kg/m2 (including 18 kg/m2 and 26 kg/m2), and weighing
             between 50-80 kg (including 50 kg and 80 kg).

          4. Subjects determined healthy by Vital signs, physical examination, laboratory tests
             (blood routine, blood biochemistry, coagulation function, urine routine, fecal occult
             blood, etc.), 12-lead electrocardiogram, chest X-ray, abdominal ultrasound, urinary
             ultrasound, without any clinically significant abnormality judged by the investigator.

          5. Subjects who are willing to comply with the contraception restrictions from signing of
             the informed consent form until 6 months after the infusion of the test drug.

          6. Subjects who can participate in the visit on time and complete the visit.

        Exclusion Criteria:

          1. Subjects with the following diseases, including but not limited to: nervous system,
             cardiovascular system, blood and lymphatic system, immune system, digestive system,
             respiratory system, metabolism and bone diseases.

          2. History of digestive tract perforation or digestive tract disease.

          3. Subjects who are allergic to Avastin® and its ingredients.

          4. History of autoimmune diseases or allergic diseases.

          5. History of clinically significant proteinuria (urine routine examination, urinary
             protein 2+and above) or proteinuria judged by the investigator.

          6. Any inherited predisposition to bleeding or to thrombosis or history of non traumatic
             hemorrhage (i.e., requiring medical intervention), thromboembolic event or any
             condition which may increase bleeding risk including clotting disorders,
             thrombocytopenia (platelet count &lt; 125000/µL) or an international normalized ratio
             (INR) higher than 1.5.

          7. Subjects who did strenuous exercise 96 hours before the test, or participate in
             intense physical activity within 30 days after the scheduled dose, including physical
             contact or impact sports;

          8. Subject with a family history of cancer or a malignant tumor within the past 5 years.

          9. Abnormal ECG with clinical significance judged by the Investigator.

         10. Subjects with relevant family history of hypertension or abnormal blood pressure at
             screening or admission to the study center (Day 1): (Systolic blood pressure ≤ 90mmHg
             or ≥ 140mmHg, or / and diastolic blood pressure ≤ 60mmHg or ≥ 90mmHg), heart rate ≤
             50bpm or ≥ 100bpm.

         11. Subjects who have acute or chronic infectious diseases and have clinical significance
             during the screening and admission studies, or hepatitis C antibody (HCV-Ab), human
             immunodeficiency virus antibody (HIV-Ab), hepatitis B surface antigen (HBsAg),
             syphilis test positive during the screening.

         12. History of prior exposure to bevacizumab or any anti VEGF monoclonal antibodies or
             proteins.

         13. Live virus vaccination within 3 months prior to study drug administration， or prior
             exposure to any other investigational monoclonal antibody within 9 months.

         14. Intake of prescribed or over the counter drugs within 5 half-life of the drug or 2
             weeks prior to the use of the test drug, or intake of herbal drugs or dietary
             supplements within 28 days prior to randomization.

         15. Use of any investigational drug in any clinical study within the 3 months prior to
             Sign informed consent.

         16. Blood loss or blood donation (including blood components donation) ≥ 400 mL or blood
             transfusion within 3 months before study drug administration.

         17. Unhealed wound ulcers or fractures, or major surgery within 2 months prior to
             randomization or expected major surgery during the study period or 2 months after the
             end of the study.

         18. Plan to receive oral or dental surgery during the study period.

         19. History of alcohol abuse or a positive alcohol breath test before study drug
             administration.

         20. History of drug abuse, or have positive drug screening results.

         21. Subjects who have more than 5 cigarettes per day within 3 months before enrollment.

         22. Others that are not in compliance with the enrollment judged by the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanghai Institute Of Biological Products Co., Ltd</last_name>
    <role>Study Director</role>
    <affiliation>SINOPHARM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>The First Affiliated Hospital</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bengbu Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aidong QU, Master</last_name>
    <phone>+86-021-62800991</phone>
    <email>quaidong1@sinopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dandan Chen, Master</last_name>
    <phone>+86-021-62800991</phone>
    <email>ddchen.sh@sinopharm.com</email>
  </overall_contact_backup>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

